Type 2 & other diabetes

Oral Glucose Tolerance Test (OGTT) ‐Derived β‐Cell Function–Based Stratification of 2‐Year Glycaemic Transitions in Chinese Adults With Prediabetes

Diabetes Obes MetabPublished Prospective cohort study

Authors' conclusion

ISSI-2 was associated with baseline glycaemic profiles and bidirectional 2-year transitions in Chinese adults with prediabetes.

Study context

Population
Chinese adults with prediabetes and complete baseline OGTT glucose and insulin measurements, multicentre lifestyle intervention cohort410 with 2-year outcomes
Participants
645 adults
Exposure
ISSI-2 and homeostasis model assessment of insulin resistance (HOMA-IR) in relation to baseline glycaemia and 2-year glycaemic transitions
Outcome
2-year progression to diabetes or reversion to normoglycemia
Follow-up
2 years
Methodological detailsmulticentre, lifestyle intervention cohort, multivariable regression
  • Multicentre
  • Lifestyle intervention cohort
  • Multivariable regression

Main finding

As reported in the abstract

Progressed to diabetes

136 participants

Reverted to normoglycemia

61 participants

Progression risk per 1-SD increase in ISSI-2, OR

0.505 (0.382-0.668) (95% CI)

Reversion likelihood per 1-SD increase in ISSI-2, OR

1.447 (1.106-1.893) (95% CI)

Observational data: associations, not effects.

Further findings

OutcomeOR (95% CI)
Progression risk by index-based group · 2 yearsDual-defect (higher HOMA-IR and lower ISSI-2)vs Low IR + higher ISSI-22.764 (1.459–5.237)

Baseline glycaemic measures vs ISSI-2

1-h PG, β per 1-SD increase in ISSI-2 (strongest association)
−1.189 mmol/L; p < 0.001
Higher ISSI-2 associated with lower FPG, 1-h PG, 2-h PG and HbA1c

Original publication

OGTT ‐Derived β‐Cell Function–Based Stratification of 2‐Year Glycaemic Transitions in Chinese Adults With Prediabetes. Diabetes Obes Metab. Published 13 September 2026. doi:10.1111/dom.71310

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.